N4 Pharma plans to change its name to Thalia Therapeutics plc
Shareholder meeting scheduled for March 17, 2026 at London offices
Name change reflects strategic shift toward RNA-based therapeutics
Trading symbol would change to THAT if approved
📖 Full Retelling
N4 Pharma plc (AIM:N4P) announced Thursday in London its intention to change its name to Thalia Therapeutics plc, subject to shareholder approval at a general meeting scheduled for March 17, 2026. The strategic name change reflects the company's transition to focus on RNA-based therapeutics development alongside its Nuvec gene delivery platform, a shift previously announced on February 24, 2026. The general meeting will be held at 10:00 am at the offices of Arch Law Limited Huckletree Bishopsgate, 8 Bishopsgate, London, where shareholders will vote on the special resolution required for the name change. The company develops Nuvec, a gene delivery system for advanced therapies targeting cancer and other diseases, with the new name intended to better represent its expanded pipeline and strategic focus on internally generated RNA assets and partnering opportunities.
Legal act by a person of adopting a different name
Name change is the legal act by a person of adopting a new name.
The procedures and ease of a name change vary between jurisdictions. In general, common law jurisdictions have looser procedures while civil law jurisdictions are more restrictive.
London is the capital and largest city of both England and the United Kingdom, with a population of 9.1 million people in 2024. Its wider metropolitan area is the largest in Western Europe, with a population of 15.1 million. London stands on the River Thames in southeast England, at the head of a 50...
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Netflix declines to match Paramount Skydance bid for Warner Bros This is where Deutsche Bank sees silver prices ending the year Gold prices steady near $5,200/oz; strong Feb gains on tap Nvidia CEO Huang said SaaSpocalypse narrative wrong, sees ’deep misunderstanding’ (South Africa Philippines Nigeria) N4 Pharma plans name change to Thalia Therapeutics By Investing.com Company News Published 02/27/2026, 02:07 AM N4 Pharma plans name change to Thalia Therapeutics 0 N4P 0.00% LONDON - N4 Pharma plc (AIM:N4P) announced Thursday it intends to change its name to Thalia Therapeutics plc, subject to shareholder approval at a general meeting scheduled for March 17, 2026. The general meeting will be held at 10:00 am at the offices of Arch Law Limited Huckletree Bishopsgate, 8 Bishopsgate, London. The proposed name change reflects the company’s transition to focus on RNA-based therapeutics development alongside its Nuvec gene delivery platform, according to a press release statement. The shift in strategic direction was previously announced on February 24, 2026. N4 Pharma develops Nuvec, a gene delivery system for advanced therapies targeting cancer and other diseases. The company stated the new name would better represent its expanded pipeline and strategic focus on internally generated RNA assets and partnering opportunities. The name change requires shareholder approval through a special resolution and subsequent issuance of a change of name certificate by Companies House. If approved, the company’s trading symbol will change to THAT, while its LEI, ISIN and SEDOL identifiers will remain unchanged. Existing share certificates will remain valid and no new certificates will be issued following the name change. The company’s website, which contains information required by AIM Rule 26, will be updated to reflect the new name after registration is completed. A notice of general meeting and proxy form has been sent to sha...
